Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

BACKGROUND: Histone deacetylase (HDAC) overexpression has been documented in various cancers and may be associated with worse outcomes. Data from early-phase studies of advanced non-small cell lung cancer (NSCLC) suggest encouraging antitumor activity with the combination of an HDAC inhibitor and ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Awad, Mark M., Le Bruchec, Yvan, Lu, Brian, Ye, Jason, Miller, JulieAnn, Lizotte, Patrick H., Cavanaugh, Megan E., Rode, Amanda J., Dumitru, Calin Dan, Spira, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451476/
https://www.ncbi.nlm.nih.gov/pubmed/34552864
http://dx.doi.org/10.3389/fonc.2021.696512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451476/
https://www.ncbi.nlm.nih.gov/pubmed/34552864
http://dx.doi.org/10.3389/fonc.2021.696512

Ejemplares similares